A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia. [Read more…]
MSCs as “Therapeutic Workhouses” in the Era of Regenerative Medicine
MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.
Toulouse, 2026 April 16th – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment
FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]
MSCs: A Multi-Version Medicinal Technology System, Part I
The Most Interesting Things Take Time
The world’s first approved product from monoclonal antibody technology was Muromonab-CD3 (Orthoclone OKT3), launched in 1986. It’s a prime example of “mAb version 1.0,” unleashed before a wave of newer, more manufacturable and better engineered products would begin to enter the market in the late-90s. Later molecular and process iterations based on “mAb 1.0” would take several decades to finally ramify into diverse platforms such as CAR-T, Bi-specific T-cell engagers (BiTEs), diagnostics, and biosensors. As a cellular technology platform, mesenchymal stem/stromal cells (MSCs) are proceeding with a story of convergent evolution. [Read more…]